Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E, Chaix ML, Peeters M, Ayouba A; ANRS 12186 Study Group.

Clin Infect Dis. 2014 Jan;58(1):99-109. doi: 10.1093/cid/cit627. Epub 2013 Sep 27.

PMID:
24076968
2.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

3.

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.

Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER).

Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254. Epub 2012 Apr 3.

PMID:
22474222
4.

Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.

Messou E, Chaix ML, Gabillard D, Yapo V, Toni TD, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):211-9. doi: 10.1097/QAI.0b013e3182a009e4.

5.

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, Taburet AM, Balkan S, Olson DM, Olaro C, Pujades-Rodríguez M.

BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.

6.

Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.

Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D.

J Antimicrob Chemother. 2015;70(6):1881-4. doi: 10.1093/jac/dkv030. Epub 2015 Feb 18.

PMID:
25698771
7.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

8.

Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.

Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R; ANRS 12-06/IMEA 012 Trial Study Group.

MedGenMed. 2007 Oct 9;9(4):7.

9.

Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64. doi: 10.1097/QAI.0b013e3182084b5a.

10.

Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo.

Muwonga J, Edidi S, Butel C, Vidal N, Monleau M, Okenge A, Mandjo JL, Mukumbi H, Muyembe JJ, Mbayo F, Nzongola DK, Delaporte E, Boillot F, Peeters M.

J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S27-33. doi: 10.1097/QAI.0b013e31821f596c.

PMID:
21857282
11.

Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .

Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Campbell NK, Taka N, Awasom C, Metzner KJ, van Lunzen J, Feldt T.

J Antimicrob Chemother. 2015 Mar;70(3):922-5. doi: 10.1093/jac/dku470. Epub 2014 Nov 26.

PMID:
25428920
12.

Detecting virological failure in HIV-infected Tanzanian children.

Mgelea EM, Kisenge R, Aboud S.

S Afr Med J. 2014 Jun 26;104(10):696-9. doi: 10.7196/samj.7807.

PMID:
25363057
13.

Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.

Kitkungvan D, Apisarnthanarak A, Laowansiri P, Mundy LM.

HIV Med. 2008 Oct;9(8):636-41. doi: 10.1111/j.1468-1293.2008.00611.x. Epub 2008 Jul 17.

14.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607
15.

How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?

Scott Braithwaite R, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T.

AIDS. 2014 Jan;28 Suppl 1:S73-83. doi: 10.1097/QAD.0000000000000110.

16.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
17.

Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.

Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM.

Lancet Infect Dis. 2010 Mar;10(3):155-66. doi: 10.1016/S1473-3099(09)70328-7. Review.

PMID:
20185094
18.

Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.

Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, Verputten M, O'Brien DP.

J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb;8(1):60-7. doi: 10.1177/1545109709331472. Epub 2009 Feb 11.

PMID:
19211930
19.

High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.

Salou M, Dagnra AY, Butel C, Vidal N, Serrano L, Takassi E, Konou AA, Houndenou S, Dapam N, Singo-Tokofaï A, Pitche P, Atakouma Y, Prince-David M, Delaporte E, Peeters M.

J Int AIDS Soc. 2016 Apr 27;19(1):20683. doi: 10.7448/IAS.19.1.20683. eCollection 2016.

20.

Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry.

Diouara AA, Ndiaye HD, Guindo I, Bangoura N, Cissé M, Edmond T, Bougoudogo F, Mboup S, Peeters M, Ayouba A, Kane NC.

J Int AIDS Soc. 2014 Dec 18;17:19315. doi: 10.7448/IAS.17.1.19315. eCollection 2014.

Supplemental Content

Support Center